Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.


(control systems)


1. In stone setting or bricklaying, to finish a mortar joint with a stroke of the trowel, simultaneously removing extruding mortar and smoothing the surface of the mortar remaining in the joint; strike off.


Said of a load-bearing member, element, etc., of a building.
References in periodicals archive ?
The intersection of DNA STR identification profiles and whole-genome sequencing has begun, and there are obvious societal implications.
Bruce Wiechert Custom Homes Inc, 838 Mountaingate Dr; STR - New single family residence; $402,132.
STR has the potential to become a valuable tool in education as it makes teaching accessible and understandable to all students and it improves the quality of education (Wald, 2010).
Factors that could affect the Company's actual results include the availability of working capital and financing sources for the development of NeoRx's product candidates, the progress and costs of clinical trials and the timing of regulatory approvals, the availability of clinical materials from third-party suppliers, NeoRx's ability to manufacture STR in a timely and cost-effective manner, NeoRx's ability to successfully commercialize product candidates, and other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2003, and Quarterly Report on Form 10- Q for the quarter ended September 30, 2004.
STR is an investigational, targeted cancer therapeutic that delivers radiation directly to cancer in the bone and bone marrow, sparing other tissues from radiation's effects.
STR is composed of a bone-targeting molecule, DOTMP, in a stable complex with the radionuclide holmium-166.
Keith Moore, CEO of STR, said, "Becoming part of IES was a natural process to assist STR in achieving its growth goals.
David Maloney of the Fred Hutchinson Cancer Research Center, Vincent Rajkumar of the Mayo Clinic, and Paul Richardson of the Dana-Farber Cancer Institute, who will share highlights from the ASCO 2004 Annual Meeting, including a discussion of the STR clinical data presented by Dr.
Keith Moore, CEO of STR, said, Becoming part of IES was a natural process to assist STR in achieving its growth goals.
NeoRx is developing STR for use with high-dose chemotherapy and autologous stem cell transplantation to treat multiple myeloma, a cancer arising in the bone marrow, and other cancers where stem cell transplantation is indicated.
The phase III pivotal trial is a multi-center, randomized, controlled study, designed to evaluate the safety and efficacy of STR in patients with primary refractory multiple myeloma.
The Company expects to announce in the next few weeks that it has opened a phase III clinical trial of STR to enrollment of patients with primary refractory multiple myeloma.